https://corcept.com/wp-content/uploads/COR-logo.svg00jeremiah@devisedesigns.comhttps://corcept.com/wp-content/uploads/COR-logo.svgjeremiah@devisedesigns.com2024-01-08 00:00:002024-01-08 00:00:00Miricorilant Reduced Liver Fat and Cardiometabolic Disease Markers in a Phase 1b, Open-Label Dose-Finding Study in Patients with Non-Alcoholic Steatohepatitis (NASH)
